youtube_live
Q3 2026 earnings • released • EPS beat +2.73% • Revenue beat +1.84%
See resultschevron_right
EXEL:NASDAQ
Exelixis Inc
$72.97
arrow_upward
+4.05%(+2.84) 1D
Nov 3, 12:05:32 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EXEL...
Open
$70.11
High
$73.17
Low
$70.11
Mkt. cap
17.83B
Avg. vol.
2.37M
Volume
890.32K
P/E ratio
21.84
52-wk high
$73.17
52-wk low
$37.58
EPS
$3.34
Beta
0.45
Shares outstanding
244.01M
No. of employees
1K
Open
$70.11
High
$73.17
Low
$70.11
Mkt. cap
17.83B
Avg. vol.
2.37M
Volume
890.32K
P/E ratio
21.84
52-wk high
$73.17
52-wk low
$37.58
EPS
$3.34
Beta
0.45
Shares outstanding
244.01M
No. of employees
1K
News stories
From web sources and news partners
Profile
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
About Exelixis Inc
CEOMichael M. Morrissey
Employees1.08K
FoundedNov 15, 1994
HeadquartersAlameda, California, United States
SectorBiotechnology
Websiteexelixis.com
Analyst ratings
Based on 15 analysts giving stock ratings to EXEL in the past 3 months
Buy
Buy
5
Hold
9
Sell
1
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for EXEL in the last 3 months.
Highest
Current $72.97
$78.00 (+6.89%)
Average
$59.15 (-18.94%)
Lowest
$41.00 (-43.81%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Robert Burns H.C. Wainwright | Buy | Reiterated | $78.00 | +6.9% | 11/02/2026 |
Stephen Willey Stifel Nicolaus | Hold | Maintained | $51.00 | -30.1% | 10/30/2026 |
Gregory Renza Truist Financial | Hold | Maintained | $60.00 | -17.8% | 10/30/2026 |
Yaron Werber TD Cowen | Buy | Maintained | $76.00 | +4.2% | 10/30/2026 |
Sean Laaman Morgan Stanley | Hold | Reiterated | $60.00 | -17.8% | 10/30/2026 |
David Lebowitz BMO Capital | Hold | Reiterated | $60.00 | -17.8% | 10/30/2026 |
Unknown Analyst Guggenheim | Hold | Maintained | - | - | 10/29/2026 |
Leonid Timashev RBC Capital | Hold | Reiterated | $58.00 | -20.5% | 10/29/2026 |
Etzer Darout Barclays | Hold | Maintained | $54.00 | -26% | 10/30/2026 |
Silvan Tuerkcan Citizens JMP | Buy | Maintained | $65.00 | -10.9% | 10/19/2026 |
Jason Gerberry Bank of America Securities | Sell | Maintained | $41.00 | -43.8% | 10/09/2026 |
Andy Hsieh William Blair | Buy | Reiterated | - | - | 09/11/2026 |
Unknown Analyst BMO Capital | Hold | Maintained | $54.00 | -26% | 09/01/2026 |
Andrew Berens Leerink Partners | Hold | Downgraded | $52.00 | -28.7% | 08/06/2026 |
Paul Choi Goldman Sachs | Buy | Maintained | $64.00 | -12.3% | 08/05/2026 |
Derek Archila Wells Fargo | Hold | Reiterated | $50.00 | -31.5% | 08/06/2026 |
Eva Fortea Verdejo Wells Fargo | Hold | Reiterated | $50.00 | -31.5% | 08/06/2026 |
Unknown Analyst Wells Fargo | Hold | Maintained | $49.00 | -32.8% | 07/13/2026 |
Ashwani Verma UBS | Hold | Reiterated | $52.00 | -28.7% | 07/02/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $47.00 | -35.6% | 03/25/2026 |
Jay Olson Oppenheimer | Hold | Maintained | $36.00 | -50.7% | 03/03/2026 |
Unknown Analyst Stephens | Buy | Maintained | $60.00 | -17.8% | 02/11/2026 |
Michael Schmidt Guggenheim | Hold | Maintained | - | - | 02/10/2026 |
Last report
Oct 29, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$0.94 / $0.92
+2.73%beat
arrow_upward
Revenue / Est. (USD)
658.70M / 646.77M
+1.84%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 598.66M | 610.81M | 628.69M | 658.70M |
Cost of goods sold | 26.48M | 19.95M | 20.66M | 26.23M |
Cost of revenue | 26.48M | 19.95M | 20.66M | 26.23M |
Research and development expenses | 213.25M | 199.92M | 211.99M | 209.48M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 123.02M | 139.60M | 147.63M | 154.56M |
Operating expense | 336.27M | 339.52M | 359.62M | 364.04M |
Total operating expenses | 362.75M | 359.47M | 380.28M | 390.27M |
Operating income | 235.91M | 251.34M | 248.41M | 268.42M |
Other non operating income | 46.00K | 219.00K | 54.00K | 47.00K |
EBT including unusual items | 252.69M | 267.69M | 262.68M | 282.78M |
EBT excluding unusual items | 253.38M | 267.69M | 262.68M | 282.78M |
Income tax expense | 8.16M | 57.22M | 50.63M | 64.69M |
Effective tax rate | 3.23% | 21.38% | 19.27% | 22.88% |
Other operating expenses | - | - | - | - |
Net income | 244.53M | 210.47M | 212.05M | 218.10M |
Net profit margin | 40.85% | 34.46% | 33.73% | 33.11% |
Earnings per share | 0.94 | 0.87 | 0.91 | 0.94 |
Interest and investment income | 17.43M | 16.13M | 14.21M | 14.32M |
Interest expense | - | - | - | - |
Net interest expenses | 17.43M | 16.13M | 14.21M | 14.32M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 242.86M | 258.29M | 255.40M | 275.36M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events